Article
Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation.
Cancer biology & therapy - 3 Jun 2018
Wang Jian, Wen Yuxin, Ding Guanggui, Ding Peikun, Zhang Lu, Liu Jing, Zhang Tengfei, Yang Lin
Abstract excerpt
Afatinib exhibits therapeutic efficacy for lung adenocarcinoma patients harboring HER2 exon 20 insertions. HER2 S310Y single site substitution was discovered in recent years and afatinib efficacy for adenocarcinoma patients harboring S310Y mutation has not been reported. We presented a case of a 41-year-old male patient with lung adenocarcinoma harboring the HER2 S310Y mutation obtained clinical response to the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.